97 related articles for article (PubMed ID: 15972137)
1. [Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
Lu XC; Zhu HL; Yao SQ; Fan H; Zhuang XM; Yang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):440-2. PubMed ID: 15972137
[TBL] [Abstract][Full Text] [Related]
2. [Amifostine used in the treatment of patients with myelodysplastic syndrome].
Li SX; Zhu HL; Lu XC; Fan H; Yao SQ; Ma J; Yang QM; Cai LL; Zhuang XM; Yang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):86-90. PubMed ID: 17490528
[TBL] [Abstract][Full Text] [Related]
3. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
4. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
5. [Short-term curative effect of amifostine combined with rhbeta-EPO on patients with pure erythroid aplasia].
Li SX; Zhu HL; Lu XC; Fan H; Guo B; Zhai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1103-6. PubMed ID: 18928605
[TBL] [Abstract][Full Text] [Related]
6. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
Tefferi A; Elliott MA; Steensma DP; Hook CC; Dispenzieria A; Hanson CA; Schroeder G; Letendre L
Leuk Res; 2001 Feb; 25(2):183-5. PubMed ID: 11166835
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
[TBL] [Abstract][Full Text] [Related]
9. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
12. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
15. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism and problem of amifostine in treating myelodysplastic syndromes].
Dang YH; Li W; Yang B; Zhu HL; Huang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1597-601. PubMed ID: 20030955
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
Invernizzi R; Pecci A; Travaglino E; Gobbi PG; Malabarba L; Ramajoli I; Ascari E
Br J Haematol; 2002 Jul; 118(1):246-50. PubMed ID: 12100155
[TBL] [Abstract][Full Text] [Related]
19. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stone RM; Bernstein SH; Demetri G; Facklam DP; Arthur K; Andersen J; Aster JC; Kufe D
Leuk Res; 1994 Oct; 18(10):769-76. PubMed ID: 7934135
[TBL] [Abstract][Full Text] [Related]
20. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
Neumeister P; Jaeger G; Eibl M; Sormann S; Zinke W; Linkesch W
Leuk Lymphoma; 2001 Jan; 40(3-4):345-9. PubMed ID: 11426556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
